nodes	percent_of_prediction	percent_of_DWPC	metapath
Desipramine—CYP2A6—esophageal cancer	0.478	0.729	CbGaD
Desipramine—ABCB1—esophageal cancer	0.178	0.271	CbGaD
Desipramine—SLC22A2—Cisplatin—esophageal cancer	0.0266	0.511	CbGbCtD
Desipramine—CYP2B6—Cisplatin—esophageal cancer	0.0138	0.265	CbGbCtD
Desipramine—ABCB1—Cisplatin—esophageal cancer	0.00707	0.136	CbGbCtD
Desipramine—SLC22A4—larynx—esophageal cancer	0.00636	0.113	CbGeAlD
Desipramine—ABCB1—Methotrexate—esophageal cancer	0.00459	0.0882	CbGbCtD
Desipramine—HTR2A—vagus nerve—esophageal cancer	0.00361	0.064	CbGeAlD
Desipramine—Paresthesia of limbs—Methotrexate—esophageal cancer	0.00233	0.0503	CcSEcCtD
Desipramine—CHRM3—exocrine gland—esophageal cancer	0.00208	0.037	CbGeAlD
Desipramine—CYP2C18—bronchus—esophageal cancer	0.00195	0.0346	CbGeAlD
Desipramine—SMPD1—digestive system—esophageal cancer	0.00185	0.0329	CbGeAlD
Desipramine—SLC22A4—neck—esophageal cancer	0.00169	0.0299	CbGeAlD
Desipramine—CHRM5—epithelium—esophageal cancer	0.00162	0.0288	CbGeAlD
Desipramine—SMPD1—lung—esophageal cancer	0.00155	0.0275	CbGeAlD
Desipramine—CYP2C18—digestive system—esophageal cancer	0.00151	0.0268	CbGeAlD
Desipramine—Inappropriate antidiuretic hormone secretion—Cisplatin—esophageal cancer	0.0014	0.0302	CcSEcCtD
Desipramine—Ileus paralytic—Capecitabine—esophageal cancer	0.00139	0.0299	CcSEcCtD
Desipramine—SLC22A2—digestive system—esophageal cancer	0.00118	0.0209	CbGeAlD
Desipramine—Sudden death—Capecitabine—esophageal cancer	0.00117	0.0253	CcSEcCtD
Desipramine—SLC22A4—bronchus—esophageal cancer	0.00113	0.0201	CbGeAlD
Desipramine—SMPD1—lymph node—esophageal cancer	0.00106	0.0188	CbGeAlD
Desipramine—ADRB1—bronchus—esophageal cancer	0.00104	0.0184	CbGeAlD
Desipramine—SLC22A4—trachea—esophageal cancer	0.00102	0.018	CbGeAlD
Desipramine—SLC22A3—smooth muscle tissue—esophageal cancer	0.00101	0.0179	CbGeAlD
Desipramine—Raised liver function tests—Methotrexate—esophageal cancer	0.000967	0.0209	CcSEcCtD
Desipramine—CHRM1—trachea—esophageal cancer	0.000896	0.0159	CbGeAlD
Desipramine—CHRM3—smooth muscle tissue—esophageal cancer	0.000874	0.0155	CbGeAlD
Desipramine—SLC22A4—digestive system—esophageal cancer	0.000874	0.0155	CbGeAlD
Desipramine—Sudden death—Methotrexate—esophageal cancer	0.000872	0.0188	CcSEcCtD
Desipramine—CYP2A6—lung—esophageal cancer	0.000833	0.0148	CbGeAlD
Desipramine—HTR2A—neck—esophageal cancer	0.000791	0.014	CbGeAlD
Desipramine—Ventricular fibrillation—Capecitabine—esophageal cancer	0.000783	0.0169	CcSEcCtD
Desipramine—Body temperature increased—Carboplatin—esophageal cancer	0.000782	0.0169	CcSEcCtD
Desipramine—SLC6A4—digestive system—esophageal cancer	0.000774	0.0137	CbGeAlD
Desipramine—ORM1—lung—esophageal cancer	0.000758	0.0135	CbGeAlD
Desipramine—SLC22A5—bronchus—esophageal cancer	0.000748	0.0133	CbGeAlD
Desipramine—Tingling sensation—Capecitabine—esophageal cancer	0.000746	0.0161	CcSEcCtD
Desipramine—SLC22A4—lung—esophageal cancer	0.00073	0.0129	CbGeAlD
Desipramine—Petechiae—Capecitabine—esophageal cancer	0.000729	0.0157	CcSEcCtD
Desipramine—SLC6A3—lung—esophageal cancer	0.000705	0.0125	CbGeAlD
Desipramine—CHRM3—digestive system—esophageal cancer	0.00069	0.0122	CbGeAlD
Desipramine—SLC22A5—trachea—esophageal cancer	0.000672	0.0119	CbGeAlD
Desipramine—ADRB1—lung—esophageal cancer	0.000669	0.0119	CbGeAlD
Desipramine—SLC22A3—lung—esophageal cancer	0.000664	0.0118	CbGeAlD
Desipramine—Ventricular extrasystoles—Capecitabine—esophageal cancer	0.000664	0.0143	CcSEcCtD
Desipramine—CYP2B6—bronchus—esophageal cancer	0.00065	0.0115	CbGeAlD
Desipramine—Nocturia—Capecitabine—esophageal cancer	0.000646	0.014	CcSEcCtD
Desipramine—SLC6A4—lung—esophageal cancer	0.000646	0.0115	CbGeAlD
Desipramine—HRH1—epithelium—esophageal cancer	0.000644	0.0114	CbGeAlD
Desipramine—CHRM1—lung—esophageal cancer	0.000644	0.0114	CbGeAlD
Desipramine—CYP2C19—digestive system—esophageal cancer	0.000641	0.0114	CbGeAlD
Desipramine—HRH1—smooth muscle tissue—esophageal cancer	0.000621	0.011	CbGeAlD
Desipramine—Coordination abnormal—Capecitabine—esophageal cancer	0.000611	0.0132	CcSEcCtD
Desipramine—Cerebrovascular accident—Cisplatin—esophageal cancer	0.000602	0.013	CcSEcCtD
Desipramine—Phosphatase alkaline increased—Capecitabine—esophageal cancer	0.0006	0.013	CcSEcCtD
Desipramine—SLC22A5—digestive system—esophageal cancer	0.000578	0.0103	CbGeAlD
Desipramine—HRH1—trachea—esophageal cancer	0.00057	0.0101	CbGeAlD
Desipramine—SLC6A2—lung—esophageal cancer	0.000569	0.0101	CbGeAlD
Desipramine—Petechiae—Methotrexate—esophageal cancer	0.000542	0.0117	CcSEcCtD
Desipramine—HTR2A—epithelium—esophageal cancer	0.000538	0.00955	CbGeAlD
Desipramine—CYP1A2—digestive system—esophageal cancer	0.000524	0.00929	CbGeAlD
Desipramine—ORM1—lymph node—esophageal cancer	0.000519	0.0092	CbGeAlD
Desipramine—HTR2A—smooth muscle tissue—esophageal cancer	0.000519	0.0092	CbGeAlD
Desipramine—DRD2—lung—esophageal cancer	0.000518	0.0092	CbGeAlD
Desipramine—CYP2B6—digestive system—esophageal cancer	0.000502	0.00891	CbGeAlD
Desipramine—Blood alkaline phosphatase increased—Capecitabine—esophageal cancer	0.0005	0.0108	CcSEcCtD
Desipramine—SLC22A4—lymph node—esophageal cancer	0.000499	0.00885	CbGeAlD
Desipramine—HRH1—digestive system—esophageal cancer	0.00049	0.0087	CbGeAlD
Desipramine—Vascular purpura—Capecitabine—esophageal cancer	0.000486	0.0105	CcSEcCtD
Desipramine—SLC22A5—lung—esophageal cancer	0.000483	0.00857	CbGeAlD
Desipramine—HTR2A—trachea—esophageal cancer	0.000476	0.00844	CbGeAlD
Desipramine—CYP2E1—digestive system—esophageal cancer	0.000471	0.00836	CbGeAlD
Desipramine—Libido decreased—Capecitabine—esophageal cancer	0.000469	0.0101	CcSEcCtD
Desipramine—SLC22A3—lymph node—esophageal cancer	0.000454	0.00806	CbGeAlD
Desipramine—Purpura—Capecitabine—esophageal cancer	0.000452	0.00975	CcSEcCtD
Desipramine—Acute coronary syndrome—Cisplatin—esophageal cancer	0.000449	0.00969	CcSEcCtD
Desipramine—Myocardial infarction—Cisplatin—esophageal cancer	0.000446	0.00963	CcSEcCtD
Desipramine—Neuropathy peripheral—Cisplatin—esophageal cancer	0.000446	0.00963	CcSEcCtD
Desipramine—Cerebrovascular accident—Capecitabine—esophageal cancer	0.000444	0.00959	CcSEcCtD
Desipramine—Stomatitis—Cisplatin—esophageal cancer	0.000443	0.00958	CcSEcCtD
Desipramine—CYP1A2—lung—esophageal cancer	0.000437	0.00776	CbGeAlD
Desipramine—Disturbance in sexual arousal—Capecitabine—esophageal cancer	0.000432	0.00933	CcSEcCtD
Desipramine—CYP2B6—lung—esophageal cancer	0.000419	0.00744	CbGeAlD
Desipramine—Urinary retention—Capecitabine—esophageal cancer	0.000414	0.00894	CcSEcCtD
Desipramine—HTR2A—digestive system—esophageal cancer	0.000409	0.00726	CbGeAlD
Desipramine—HRH1—lung—esophageal cancer	0.000409	0.00726	CbGeAlD
Desipramine—Ataxia—Capecitabine—esophageal cancer	0.000409	0.00884	CcSEcCtD
Desipramine—Liver function test abnormal—Capecitabine—esophageal cancer	0.000402	0.00868	CcSEcCtD
Desipramine—Gynaecomastia—Methotrexate—esophageal cancer	0.000399	0.00863	CcSEcCtD
Desipramine—CYP2E1—lung—esophageal cancer	0.000393	0.00698	CbGeAlD
Desipramine—SLC6A2—lymph node—esophageal cancer	0.000389	0.0069	CbGeAlD
Desipramine—Tinnitus—Cisplatin—esophageal cancer	0.000381	0.00823	CcSEcCtD
Desipramine—Flushing—Cisplatin—esophageal cancer	0.000379	0.00819	CcSEcCtD
Desipramine—CYP3A4—digestive system—esophageal cancer	0.000379	0.00673	CbGeAlD
Desipramine—CYP2D6—digestive system—esophageal cancer	0.000373	0.00662	CbGeAlD
Desipramine—Carbamazepine—ABCC2—esophageal cancer	0.00037	0.164	CrCbGaD
Desipramine—Arrhythmia—Cisplatin—esophageal cancer	0.000365	0.00788	CcSEcCtD
Desipramine—Alopecia—Cisplatin—esophageal cancer	0.000361	0.0078	CcSEcCtD
Desipramine—ABCB1—epithelium—esophageal cancer	0.000353	0.00626	CbGeAlD
Desipramine—Weight increased—Capecitabine—esophageal cancer	0.000342	0.00739	CcSEcCtD
Desipramine—HTR2A—lung—esophageal cancer	0.000342	0.00607	CbGeAlD
Desipramine—Vision blurred—Cisplatin—esophageal cancer	0.000335	0.00724	CcSEcCtD
Desipramine—Depression—Capecitabine—esophageal cancer	0.000334	0.00722	CcSEcCtD
Desipramine—Tremor—Cisplatin—esophageal cancer	0.000333	0.0072	CcSEcCtD
Desipramine—Acute coronary syndrome—Capecitabine—esophageal cancer	0.000331	0.00714	CcSEcCtD
Desipramine—Cerebrovascular accident—Methotrexate—esophageal cancer	0.000331	0.00714	CcSEcCtD
Desipramine—SLC22A5—lymph node—esophageal cancer	0.00033	0.00586	CbGeAlD
Desipramine—Ill-defined disorder—Cisplatin—esophageal cancer	0.00033	0.00713	CcSEcCtD
Desipramine—Neuropathy peripheral—Capecitabine—esophageal cancer	0.000329	0.0071	CcSEcCtD
Desipramine—Myocardial infarction—Capecitabine—esophageal cancer	0.000329	0.0071	CcSEcCtD
Desipramine—Stomatitis—Capecitabine—esophageal cancer	0.000327	0.00706	CcSEcCtD
Desipramine—Jaundice—Capecitabine—esophageal cancer	0.000327	0.00706	CcSEcCtD
Desipramine—Malaise—Cisplatin—esophageal cancer	0.000321	0.00693	CcSEcCtD
Desipramine—Agranulocytosis—Capecitabine—esophageal cancer	0.000313	0.00676	CcSEcCtD
Desipramine—ABCB1—trachea—esophageal cancer	0.000312	0.00553	CbGeAlD
Desipramine—Convulsion—Cisplatin—esophageal cancer	0.000308	0.00665	CcSEcCtD
Desipramine—Ataxia—Methotrexate—esophageal cancer	0.000305	0.00658	CcSEcCtD
Desipramine—Anxiety—Cisplatin—esophageal cancer	0.000302	0.00652	CcSEcCtD
Desipramine—Hepatitis—Capecitabine—esophageal cancer	0.000301	0.0065	CcSEcCtD
Desipramine—Hypoaesthesia—Capecitabine—esophageal cancer	0.0003	0.00647	CcSEcCtD
Desipramine—Liver function test abnormal—Methotrexate—esophageal cancer	0.000299	0.00646	CcSEcCtD
Desipramine—Discomfort—Cisplatin—esophageal cancer	0.000299	0.00646	CcSEcCtD
Desipramine—Protriptyline—ABCB1—esophageal cancer	0.000293	0.13	CrCbGaD
Desipramine—Oedema—Cisplatin—esophageal cancer	0.00029	0.00627	CcSEcCtD
Desipramine—Thrombocytopenia—Cisplatin—esophageal cancer	0.000284	0.00614	CcSEcCtD
Desipramine—Tachycardia—Cisplatin—esophageal cancer	0.000283	0.00612	CcSEcCtD
Desipramine—Tinnitus—Capecitabine—esophageal cancer	0.000281	0.00606	CcSEcCtD
Desipramine—HRH1—lymph node—esophageal cancer	0.00028	0.00497	CbGeAlD
Desipramine—Flushing—Capecitabine—esophageal cancer	0.000279	0.00604	CcSEcCtD
Desipramine—Eosinophilia—Methotrexate—esophageal cancer	0.000277	0.00599	CcSEcCtD
Desipramine—Anorexia—Cisplatin—esophageal cancer	0.000277	0.00597	CcSEcCtD
Desipramine—Hypotension—Cisplatin—esophageal cancer	0.000271	0.00586	CcSEcCtD
Desipramine—Arrhythmia—Capecitabine—esophageal cancer	0.000269	0.00581	CcSEcCtD
Desipramine—ABCB1—digestive system—esophageal cancer	0.000268	0.00476	CbGeAlD
Desipramine—Alopecia—Capecitabine—esophageal cancer	0.000266	0.00575	CcSEcCtD
Desipramine—Paraesthesia—Cisplatin—esophageal cancer	0.000261	0.00563	CcSEcCtD
Desipramine—Erectile dysfunction—Methotrexate—esophageal cancer	0.000258	0.00557	CcSEcCtD
Desipramine—Dysgeusia—Capecitabine—esophageal cancer	0.000257	0.00554	CcSEcCtD
Desipramine—Decreased appetite—Cisplatin—esophageal cancer	0.000252	0.00545	CcSEcCtD
Desipramine—Drowsiness—Methotrexate—esophageal cancer	0.00025	0.00539	CcSEcCtD
Desipramine—Depression—Methotrexate—esophageal cancer	0.000249	0.00538	CcSEcCtD
Desipramine—Vision blurred—Capecitabine—esophageal cancer	0.000247	0.00534	CcSEcCtD
Desipramine—Tremor—Capecitabine—esophageal cancer	0.000246	0.0053	CcSEcCtD
Desipramine—Stomatitis—Methotrexate—esophageal cancer	0.000243	0.00526	CcSEcCtD
Desipramine—Ill-defined disorder—Capecitabine—esophageal cancer	0.000243	0.00525	CcSEcCtD
Desipramine—Feeling abnormal—Cisplatin—esophageal cancer	0.000239	0.00517	CcSEcCtD
Desipramine—Malaise—Capecitabine—esophageal cancer	0.000236	0.00511	CcSEcCtD
Desipramine—Agranulocytosis—Methotrexate—esophageal cancer	0.000233	0.00503	CcSEcCtD
Desipramine—Palpitations—Capecitabine—esophageal cancer	0.000232	0.005	CcSEcCtD
Desipramine—Nortriptyline—PTGS1—esophageal cancer	0.000231	0.102	CrCbGaD
Desipramine—Body temperature increased—Cisplatin—esophageal cancer	0.000229	0.00495	CcSEcCtD
Desipramine—Hypertension—Capecitabine—esophageal cancer	0.000226	0.00489	CcSEcCtD
Desipramine—Hepatitis—Methotrexate—esophageal cancer	0.000224	0.00484	CcSEcCtD
Desipramine—ABCB1—lung—esophageal cancer	0.000224	0.00398	CbGeAlD
Desipramine—Anxiety—Capecitabine—esophageal cancer	0.000222	0.0048	CcSEcCtD
Desipramine—Discomfort—Capecitabine—esophageal cancer	0.00022	0.00476	CcSEcCtD
Desipramine—Dry mouth—Capecitabine—esophageal cancer	0.000218	0.00471	CcSEcCtD
Desipramine—Epinastine—ABCB1—esophageal cancer	0.000217	0.0962	CrCbGaD
Desipramine—Confusional state—Capecitabine—esophageal cancer	0.000216	0.00466	CcSEcCtD
Desipramine—Oedema—Capecitabine—esophageal cancer	0.000214	0.00462	CcSEcCtD
Desipramine—Thrombocytopenia—Capecitabine—esophageal cancer	0.000209	0.00452	CcSEcCtD
Desipramine—Tinnitus—Methotrexate—esophageal cancer	0.000209	0.00451	CcSEcCtD
Desipramine—Tachycardia—Capecitabine—esophageal cancer	0.000209	0.00451	CcSEcCtD
Desipramine—Asthenia—Cisplatin—esophageal cancer	0.000208	0.0045	CcSEcCtD
Desipramine—Anorexia—Capecitabine—esophageal cancer	0.000204	0.0044	CcSEcCtD
Desipramine—Hypotension—Capecitabine—esophageal cancer	0.0002	0.00432	CcSEcCtD
Desipramine—Diarrhoea—Cisplatin—esophageal cancer	0.000199	0.00429	CcSEcCtD
Desipramine—Alopecia—Methotrexate—esophageal cancer	0.000198	0.00428	CcSEcCtD
Desipramine—Insomnia—Capecitabine—esophageal cancer	0.000193	0.00418	CcSEcCtD
Desipramine—Paraesthesia—Capecitabine—esophageal cancer	0.000192	0.00415	CcSEcCtD
Desipramine—Dysgeusia—Methotrexate—esophageal cancer	0.000191	0.00413	CcSEcCtD
Desipramine—Dyspepsia—Capecitabine—esophageal cancer	0.000188	0.00407	CcSEcCtD
Desipramine—Maprotiline—ABCB1—esophageal cancer	0.000187	0.0828	CrCbGaD
Desipramine—Decreased appetite—Capecitabine—esophageal cancer	0.000186	0.00402	CcSEcCtD
Desipramine—Vomiting—Cisplatin—esophageal cancer	0.000184	0.00399	CcSEcCtD
Desipramine—Fatigue—Capecitabine—esophageal cancer	0.000184	0.00398	CcSEcCtD
Desipramine—Vision blurred—Methotrexate—esophageal cancer	0.000184	0.00397	CcSEcCtD
Desipramine—Rash—Cisplatin—esophageal cancer	0.000183	0.00395	CcSEcCtD
Desipramine—Constipation—Capecitabine—esophageal cancer	0.000183	0.00395	CcSEcCtD
Desipramine—Dermatitis—Cisplatin—esophageal cancer	0.000183	0.00395	CcSEcCtD
Desipramine—Ill-defined disorder—Methotrexate—esophageal cancer	0.000181	0.00391	CcSEcCtD
Desipramine—Feeling abnormal—Capecitabine—esophageal cancer	0.000176	0.00381	CcSEcCtD
Desipramine—Malaise—Methotrexate—esophageal cancer	0.000176	0.0038	CcSEcCtD
Desipramine—Nausea—Cisplatin—esophageal cancer	0.000172	0.00372	CcSEcCtD
Desipramine—Urticaria—Capecitabine—esophageal cancer	0.00017	0.00367	CcSEcCtD
Desipramine—Abdominal pain—Capecitabine—esophageal cancer	0.000169	0.00365	CcSEcCtD
Desipramine—Body temperature increased—Capecitabine—esophageal cancer	0.000169	0.00365	CcSEcCtD
Desipramine—Convulsion—Methotrexate—esophageal cancer	0.000169	0.00365	CcSEcCtD
Desipramine—Discomfort—Methotrexate—esophageal cancer	0.000164	0.00354	CcSEcCtD
Desipramine—Triflupromazine—ABCB1—esophageal cancer	0.000163	0.0724	CrCbGaD
Desipramine—Confusional state—Methotrexate—esophageal cancer	0.000161	0.00347	CcSEcCtD
Desipramine—Thrombocytopenia—Methotrexate—esophageal cancer	0.000156	0.00337	CcSEcCtD
Desipramine—Asthenia—Capecitabine—esophageal cancer	0.000153	0.00331	CcSEcCtD
Desipramine—ABCB1—lymph node—esophageal cancer	0.000153	0.00272	CbGeAlD
Desipramine—Anorexia—Methotrexate—esophageal cancer	0.000152	0.00328	CcSEcCtD
Desipramine—Pruritus—Capecitabine—esophageal cancer	0.000151	0.00327	CcSEcCtD
Desipramine—Hypotension—Methotrexate—esophageal cancer	0.000149	0.00321	CcSEcCtD
Desipramine—Diarrhoea—Capecitabine—esophageal cancer	0.000146	0.00316	CcSEcCtD
Desipramine—Insomnia—Methotrexate—esophageal cancer	0.000144	0.00311	CcSEcCtD
Desipramine—Paraesthesia—Methotrexate—esophageal cancer	0.000143	0.00309	CcSEcCtD
Desipramine—Somnolence—Methotrexate—esophageal cancer	0.000142	0.00306	CcSEcCtD
Desipramine—Dizziness—Capecitabine—esophageal cancer	0.000141	0.00306	CcSEcCtD
Desipramine—Dyspepsia—Methotrexate—esophageal cancer	0.00014	0.00303	CcSEcCtD
Desipramine—Decreased appetite—Methotrexate—esophageal cancer	0.000138	0.00299	CcSEcCtD
Desipramine—Fatigue—Methotrexate—esophageal cancer	0.000137	0.00297	CcSEcCtD
Desipramine—Carbamazepine—ABCB1—esophageal cancer	0.000136	0.0604	CrCbGaD
Desipramine—Vomiting—Capecitabine—esophageal cancer	0.000136	0.00294	CcSEcCtD
Desipramine—Rash—Capecitabine—esophageal cancer	0.000135	0.00291	CcSEcCtD
Desipramine—Dermatitis—Capecitabine—esophageal cancer	0.000135	0.00291	CcSEcCtD
Desipramine—Headache—Capecitabine—esophageal cancer	0.000134	0.00289	CcSEcCtD
Desipramine—Feeling abnormal—Methotrexate—esophageal cancer	0.000131	0.00283	CcSEcCtD
Desipramine—Nausea—Capecitabine—esophageal cancer	0.000127	0.00274	CcSEcCtD
Desipramine—Urticaria—Methotrexate—esophageal cancer	0.000126	0.00273	CcSEcCtD
Desipramine—Body temperature increased—Methotrexate—esophageal cancer	0.000126	0.00272	CcSEcCtD
Desipramine—Abdominal pain—Methotrexate—esophageal cancer	0.000126	0.00272	CcSEcCtD
Desipramine—Clomipramine—ABCB1—esophageal cancer	0.000115	0.0509	CrCbGaD
Desipramine—Asthenia—Methotrexate—esophageal cancer	0.000114	0.00247	CcSEcCtD
Desipramine—Pruritus—Methotrexate—esophageal cancer	0.000113	0.00243	CcSEcCtD
Desipramine—Diarrhoea—Methotrexate—esophageal cancer	0.000109	0.00235	CcSEcCtD
Desipramine—Trimipramine—ABCB1—esophageal cancer	0.000106	0.0469	CrCbGaD
Desipramine—Dizziness—Methotrexate—esophageal cancer	0.000105	0.00227	CcSEcCtD
Desipramine—Promethazine—ABCB1—esophageal cancer	0.000102	0.0451	CrCbGaD
Desipramine—Vomiting—Methotrexate—esophageal cancer	0.000101	0.00219	CcSEcCtD
Desipramine—Doxepin—ABCB1—esophageal cancer	0.000101	0.0447	CrCbGaD
Desipramine—Rash—Methotrexate—esophageal cancer	0.0001	0.00217	CcSEcCtD
Desipramine—Dermatitis—Methotrexate—esophageal cancer	0.0001	0.00217	CcSEcCtD
Desipramine—Headache—Methotrexate—esophageal cancer	9.98e-05	0.00215	CcSEcCtD
Desipramine—Nausea—Methotrexate—esophageal cancer	9.46e-05	0.00204	CcSEcCtD
Desipramine—Chlorpromazine—ABCB1—esophageal cancer	7.87e-05	0.0349	CrCbGaD
Desipramine—Imipramine—ABCB1—esophageal cancer	7.83e-05	0.0348	CrCbGaD
Desipramine—Amitriptyline—ABCB1—esophageal cancer	7.78e-05	0.0345	CrCbGaD
Desipramine—CYP2A6—Metabolism—CREBBP—esophageal cancer	7.45e-06	3.98e-05	CbGpPWpGaD
Desipramine—CYP3A4—Metabolism—GAPDH—esophageal cancer	7.42e-06	3.96e-05	CbGpPWpGaD
Desipramine—CHRM4—Signaling by GPCR—PIK3CA—esophageal cancer	7.42e-06	3.96e-05	CbGpPWpGaD
Desipramine—CYP3A4—Metabolism—CRABP1—esophageal cancer	7.35e-06	3.92e-05	CbGpPWpGaD
Desipramine—DRD2—Signaling Pathways—HIF1A—esophageal cancer	7.33e-06	3.91e-05	CbGpPWpGaD
Desipramine—CHRM4—Signaling Pathways—ERBB2—esophageal cancer	7.28e-06	3.89e-05	CbGpPWpGaD
Desipramine—SLC22A2—Metabolism—NOS3—esophageal cancer	7.27e-06	3.88e-05	CbGpPWpGaD
Desipramine—HTR2A—Signaling Pathways—HIF1A—esophageal cancer	7.22e-06	3.85e-05	CbGpPWpGaD
Desipramine—HRH1—Signaling Pathways—HIF1A—esophageal cancer	7.2e-06	3.84e-05	CbGpPWpGaD
Desipramine—CHRM1—Signaling Pathways—HIF1A—esophageal cancer	7.18e-06	3.83e-05	CbGpPWpGaD
Desipramine—CHRM3—Signaling Pathways—HIF1A—esophageal cancer	7.15e-06	3.82e-05	CbGpPWpGaD
Desipramine—CYP2D6—Metabolism—CYP19A1—esophageal cancer	7.14e-06	3.81e-05	CbGpPWpGaD
Desipramine—ADRB1—Signaling Pathways—CREBBP—esophageal cancer	7.13e-06	3.81e-05	CbGpPWpGaD
Desipramine—CHRM5—Signaling by GPCR—PIK3CA—esophageal cancer	7.1e-06	3.79e-05	CbGpPWpGaD
Desipramine—CHRM2—Signaling Pathways—HIF1A—esophageal cancer	7.08e-06	3.78e-05	CbGpPWpGaD
Desipramine—CYP2C19—Metabolism—HMOX1—esophageal cancer	7.08e-06	3.78e-05	CbGpPWpGaD
Desipramine—DRD2—Signaling Pathways—KDR—esophageal cancer	7.01e-06	3.74e-05	CbGpPWpGaD
Desipramine—ADRB1—Signaling by GPCR—EGFR—esophageal cancer	7.01e-06	3.74e-05	CbGpPWpGaD
Desipramine—CYP3A4—Metabolism—GNG7—esophageal cancer	6.99e-06	3.73e-05	CbGpPWpGaD
Desipramine—CHRM3—Metabolism—CREBBP—esophageal cancer	6.99e-06	3.73e-05	CbGpPWpGaD
Desipramine—ADRB2—Signaling Pathways—CREBBP—esophageal cancer	6.98e-06	3.72e-05	CbGpPWpGaD
Desipramine—CHRM5—Signaling Pathways—ERBB2—esophageal cancer	6.97e-06	3.72e-05	CbGpPWpGaD
Desipramine—CYP2C19—Metabolism of lipids and lipoproteins—EP300—esophageal cancer	6.95e-06	3.71e-05	CbGpPWpGaD
Desipramine—ABCB1—Metabolism—HMOX1—esophageal cancer	6.91e-06	3.69e-05	CbGpPWpGaD
Desipramine—HTR2A—Signaling Pathways—KDR—esophageal cancer	6.9e-06	3.68e-05	CbGpPWpGaD
Desipramine—HRH1—Signaling Pathways—KDR—esophageal cancer	6.89e-06	3.68e-05	CbGpPWpGaD
Desipramine—CHRM1—Signaling Pathways—KDR—esophageal cancer	6.86e-06	3.66e-05	CbGpPWpGaD
Desipramine—ADRB2—Signaling by GPCR—EGFR—esophageal cancer	6.86e-06	3.66e-05	CbGpPWpGaD
Desipramine—CHRM3—Signaling Pathways—KDR—esophageal cancer	6.84e-06	3.65e-05	CbGpPWpGaD
Desipramine—HTR1A—Signaling Pathways—CREBBP—esophageal cancer	6.82e-06	3.64e-05	CbGpPWpGaD
Desipramine—CYP2C19—Metabolism—ABCB1—esophageal cancer	6.8e-06	3.63e-05	CbGpPWpGaD
Desipramine—HTR2C—Signaling Pathways—CREBBP—esophageal cancer	6.79e-06	3.62e-05	CbGpPWpGaD
Desipramine—CHRM2—Signaling Pathways—KDR—esophageal cancer	6.78e-06	3.62e-05	CbGpPWpGaD
Desipramine—SLC22A1—Metabolism—NOS3—esophageal cancer	6.77e-06	3.62e-05	CbGpPWpGaD
Desipramine—HTR1A—Signaling by GPCR—EGFR—esophageal cancer	6.7e-06	3.58e-05	CbGpPWpGaD
Desipramine—ADRB1—GPCR downstream signaling—PIK3CA—esophageal cancer	6.7e-06	3.58e-05	CbGpPWpGaD
Desipramine—CYP2A6—Metabolism—NOS3—esophageal cancer	6.67e-06	3.56e-05	CbGpPWpGaD
Desipramine—HTR2C—Signaling by GPCR—EGFR—esophageal cancer	6.67e-06	3.56e-05	CbGpPWpGaD
Desipramine—SLC22A2—Metabolism—PTGS2—esophageal cancer	6.65e-06	3.55e-05	CbGpPWpGaD
Desipramine—DRD2—Signaling Pathways—NOTCH1—esophageal cancer	6.61e-06	3.53e-05	CbGpPWpGaD
Desipramine—ADRB2—GPCR downstream signaling—PIK3CA—esophageal cancer	6.55e-06	3.5e-05	CbGpPWpGaD
Desipramine—CYP3A4—Metabolism—ALDH2—esophageal cancer	6.55e-06	3.5e-05	CbGpPWpGaD
Desipramine—SLC22A3—Metabolism—PIK3CA—esophageal cancer	6.52e-06	3.48e-05	CbGpPWpGaD
Desipramine—CYP2D6—Metabolism—HMOX1—esophageal cancer	6.51e-06	3.48e-05	CbGpPWpGaD
Desipramine—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—esophageal cancer	6.51e-06	3.47e-05	CbGpPWpGaD
Desipramine—HTR2A—Signaling Pathways—NOTCH1—esophageal cancer	6.5e-06	3.47e-05	CbGpPWpGaD
Desipramine—HRH1—Signaling Pathways—NOTCH1—esophageal cancer	6.49e-06	3.46e-05	CbGpPWpGaD
Desipramine—CHRM1—Signaling Pathways—NOTCH1—esophageal cancer	6.47e-06	3.45e-05	CbGpPWpGaD
Desipramine—CHRM3—Signaling Pathways—NOTCH1—esophageal cancer	6.45e-06	3.44e-05	CbGpPWpGaD
Desipramine—CHRM4—Signaling Pathways—CCND1—esophageal cancer	6.43e-06	3.43e-05	CbGpPWpGaD
Desipramine—CYP1A2—Metabolism—CYP1B1—esophageal cancer	6.43e-06	3.43e-05	CbGpPWpGaD
Desipramine—HTR1A—GPCR downstream signaling—PIK3CA—esophageal cancer	6.41e-06	3.42e-05	CbGpPWpGaD
Desipramine—ADRB1—Signaling Pathways—NOS3—esophageal cancer	6.39e-06	3.41e-05	CbGpPWpGaD
Desipramine—CHRM2—Signaling Pathways—NOTCH1—esophageal cancer	6.38e-06	3.41e-05	CbGpPWpGaD
Desipramine—HTR2C—GPCR downstream signaling—PIK3CA—esophageal cancer	6.37e-06	3.4e-05	CbGpPWpGaD
Desipramine—CHRM3—Metabolism—NOS3—esophageal cancer	6.26e-06	3.34e-05	CbGpPWpGaD
Desipramine—CYP2D6—Metabolism—ABCB1—esophageal cancer	6.25e-06	3.34e-05	CbGpPWpGaD
Desipramine—ADRB2—Signaling Pathways—NOS3—esophageal cancer	6.25e-06	3.33e-05	CbGpPWpGaD
Desipramine—CYP3A4—Metabolism—GSTT1—esophageal cancer	6.23e-06	3.33e-05	CbGpPWpGaD
Desipramine—CHRM4—Signaling Pathways—CDKN1A—esophageal cancer	6.22e-06	3.32e-05	CbGpPWpGaD
Desipramine—SLC22A1—Metabolism—PTGS2—esophageal cancer	6.2e-06	3.31e-05	CbGpPWpGaD
Desipramine—CYP2C18—Metabolism—PIK3CA—esophageal cancer	6.16e-06	3.29e-05	CbGpPWpGaD
Desipramine—CHRM5—Signaling Pathways—CCND1—esophageal cancer	6.16e-06	3.29e-05	CbGpPWpGaD
Desipramine—CYP3A4—Metabolism—CYP2A6—esophageal cancer	6.16e-06	3.29e-05	CbGpPWpGaD
Desipramine—HTR1A—Signaling Pathways—NOS3—esophageal cancer	6.11e-06	3.26e-05	CbGpPWpGaD
Desipramine—CYP2A6—Metabolism—PTGS2—esophageal cancer	6.1e-06	3.26e-05	CbGpPWpGaD
Desipramine—ADRB1—Signaling by GPCR—PIK3CA—esophageal cancer	6.08e-06	3.25e-05	CbGpPWpGaD
Desipramine—HTR2C—Signaling Pathways—NOS3—esophageal cancer	6.08e-06	3.24e-05	CbGpPWpGaD
Desipramine—CYP1A2—Metabolism—CYP19A1—esophageal cancer	6.05e-06	3.23e-05	CbGpPWpGaD
Desipramine—CYP2B6—Metabolism—CREBBP—esophageal cancer	6.01e-06	3.21e-05	CbGpPWpGaD
Desipramine—DRD2—Signaling Pathways—CREBBP—esophageal cancer	5.99e-06	3.2e-05	CbGpPWpGaD
Desipramine—ADRB1—Signaling Pathways—ERBB2—esophageal cancer	5.97e-06	3.19e-05	CbGpPWpGaD
Desipramine—CHRM5—Signaling Pathways—CDKN1A—esophageal cancer	5.96e-06	3.18e-05	CbGpPWpGaD
Desipramine—ADRB2—Signaling by GPCR—PIK3CA—esophageal cancer	5.95e-06	3.18e-05	CbGpPWpGaD
Desipramine—CHRM4—Signaling Pathways—EP300—esophageal cancer	5.92e-06	3.16e-05	CbGpPWpGaD
Desipramine—HTR2A—Signaling Pathways—CREBBP—esophageal cancer	5.89e-06	3.15e-05	CbGpPWpGaD
Desipramine—CYP2E1—Metabolism—CREBBP—esophageal cancer	5.89e-06	3.14e-05	CbGpPWpGaD
Desipramine—DRD2—Signaling by GPCR—EGFR—esophageal cancer	5.89e-06	3.14e-05	CbGpPWpGaD
Desipramine—HRH1—Signaling Pathways—CREBBP—esophageal cancer	5.88e-06	3.14e-05	CbGpPWpGaD
Desipramine—CHRM1—Signaling Pathways—CREBBP—esophageal cancer	5.86e-06	3.13e-05	CbGpPWpGaD
Desipramine—CHRM3—Signaling Pathways—CREBBP—esophageal cancer	5.84e-06	3.12e-05	CbGpPWpGaD
Desipramine—ADRB2—Signaling Pathways—ERBB2—esophageal cancer	5.84e-06	3.12e-05	CbGpPWpGaD
Desipramine—CYP3A4—Metabolism—ENO1—esophageal cancer	5.84e-06	3.12e-05	CbGpPWpGaD
Desipramine—CYP3A4—Metabolism—PTGS1—esophageal cancer	5.84e-06	3.12e-05	CbGpPWpGaD
Desipramine—HTR1A—Signaling by GPCR—PIK3CA—esophageal cancer	5.82e-06	3.11e-05	CbGpPWpGaD
Desipramine—HTR2A—Signaling by GPCR—EGFR—esophageal cancer	5.79e-06	3.09e-05	CbGpPWpGaD
Desipramine—HTR2C—Signaling by GPCR—PIK3CA—esophageal cancer	5.79e-06	3.09e-05	CbGpPWpGaD
Desipramine—CHRM2—Signaling Pathways—CREBBP—esophageal cancer	5.79e-06	3.09e-05	CbGpPWpGaD
Desipramine—HRH1—Signaling by GPCR—EGFR—esophageal cancer	5.78e-06	3.08e-05	CbGpPWpGaD
Desipramine—CHRM1—Signaling by GPCR—EGFR—esophageal cancer	5.76e-06	3.07e-05	CbGpPWpGaD
Desipramine—CYP3A4—Metabolism—PSME2—esophageal cancer	5.75e-06	3.07e-05	CbGpPWpGaD
Desipramine—CYP3A4—Metabolism—PSME1—esophageal cancer	5.75e-06	3.07e-05	CbGpPWpGaD
Desipramine—CHRM3—Signaling by GPCR—EGFR—esophageal cancer	5.74e-06	3.06e-05	CbGpPWpGaD
Desipramine—CHRM3—Metabolism—PTGS2—esophageal cancer	5.72e-06	3.05e-05	CbGpPWpGaD
Desipramine—HTR1A—Signaling Pathways—ERBB2—esophageal cancer	5.71e-06	3.05e-05	CbGpPWpGaD
Desipramine—CHRM2—Signaling by GPCR—EGFR—esophageal cancer	5.69e-06	3.04e-05	CbGpPWpGaD
Desipramine—HTR2C—Signaling Pathways—ERBB2—esophageal cancer	5.68e-06	3.03e-05	CbGpPWpGaD
Desipramine—CHRM5—Signaling Pathways—EP300—esophageal cancer	5.67e-06	3.03e-05	CbGpPWpGaD
Desipramine—DRD2—GPCR downstream signaling—PIK3CA—esophageal cancer	5.63e-06	3e-05	CbGpPWpGaD
Desipramine—HTR2A—GPCR downstream signaling—PIK3CA—esophageal cancer	5.54e-06	2.95e-05	CbGpPWpGaD
Desipramine—SLC22A2—Metabolism—EP300—esophageal cancer	5.53e-06	2.95e-05	CbGpPWpGaD
Desipramine—HRH1—GPCR downstream signaling—PIK3CA—esophageal cancer	5.52e-06	2.95e-05	CbGpPWpGaD
Desipramine—CYP1A2—Metabolism—HMOX1—esophageal cancer	5.52e-06	2.95e-05	CbGpPWpGaD
Desipramine—CHRM1—GPCR downstream signaling—PIK3CA—esophageal cancer	5.51e-06	2.94e-05	CbGpPWpGaD
Desipramine—CHRM3—GPCR downstream signaling—PIK3CA—esophageal cancer	5.49e-06	2.93e-05	CbGpPWpGaD
Desipramine—CHRM2—GPCR downstream signaling—PIK3CA—esophageal cancer	5.44e-06	2.9e-05	CbGpPWpGaD
Desipramine—CYP1A2—Metabolism of lipids and lipoproteins—EP300—esophageal cancer	5.41e-06	2.89e-05	CbGpPWpGaD
Desipramine—CYP2B6—Metabolism—NOS3—esophageal cancer	5.38e-06	2.87e-05	CbGpPWpGaD
Desipramine—DRD2—Signaling Pathways—NOS3—esophageal cancer	5.36e-06	2.86e-05	CbGpPWpGaD
Desipramine—CYP1A2—Metabolism—ABCB1—esophageal cancer	5.3e-06	2.83e-05	CbGpPWpGaD
Desipramine—ADRB1—Signaling Pathways—CCND1—esophageal cancer	5.28e-06	2.82e-05	CbGpPWpGaD
Desipramine—HTR2A—Signaling Pathways—NOS3—esophageal cancer	5.28e-06	2.82e-05	CbGpPWpGaD
Desipramine—CYP2E1—Metabolism—NOS3—esophageal cancer	5.27e-06	2.81e-05	CbGpPWpGaD
Desipramine—HRH1—Signaling Pathways—NOS3—esophageal cancer	5.27e-06	2.81e-05	CbGpPWpGaD
Desipramine—CHRM1—Signaling Pathways—NOS3—esophageal cancer	5.25e-06	2.8e-05	CbGpPWpGaD
Desipramine—CHRM3—Signaling Pathways—NOS3—esophageal cancer	5.23e-06	2.79e-05	CbGpPWpGaD
Desipramine—CHRM2—Signaling Pathways—NOS3—esophageal cancer	5.18e-06	2.77e-05	CbGpPWpGaD
Desipramine—ADRB2—Signaling Pathways—CCND1—esophageal cancer	5.16e-06	2.76e-05	CbGpPWpGaD
Desipramine—CHRM4—Signaling Pathways—MYC—esophageal cancer	5.16e-06	2.75e-05	CbGpPWpGaD
Desipramine—SLC22A1—Metabolism—EP300—esophageal cancer	5.15e-06	2.75e-05	CbGpPWpGaD
Desipramine—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CA—esophageal cancer	5.14e-06	2.74e-05	CbGpPWpGaD
Desipramine—DRD2—Signaling by GPCR—PIK3CA—esophageal cancer	5.11e-06	2.73e-05	CbGpPWpGaD
Desipramine—ADRB1—Signaling Pathways—CDKN1A—esophageal cancer	5.11e-06	2.72e-05	CbGpPWpGaD
Desipramine—CYP2A6—Metabolism—EP300—esophageal cancer	5.08e-06	2.71e-05	CbGpPWpGaD
Desipramine—HTR1A—Signaling Pathways—CCND1—esophageal cancer	5.05e-06	2.69e-05	CbGpPWpGaD
Desipramine—CHRM4—Signaling Pathways—EGFR—esophageal cancer	5.05e-06	2.69e-05	CbGpPWpGaD
Desipramine—HTR2A—Signaling by GPCR—PIK3CA—esophageal cancer	5.03e-06	2.68e-05	CbGpPWpGaD
Desipramine—HTR2C—Signaling Pathways—CCND1—esophageal cancer	5.02e-06	2.68e-05	CbGpPWpGaD
Desipramine—DRD2—Signaling Pathways—ERBB2—esophageal cancer	5.02e-06	2.68e-05	CbGpPWpGaD
Desipramine—HRH1—Signaling by GPCR—PIK3CA—esophageal cancer	5.02e-06	2.68e-05	CbGpPWpGaD
Desipramine—CHRM1—Signaling by GPCR—PIK3CA—esophageal cancer	5e-06	2.67e-05	CbGpPWpGaD
Desipramine—ADRB2—Signaling Pathways—CDKN1A—esophageal cancer	4.99e-06	2.67e-05	CbGpPWpGaD
Desipramine—CHRM3—Signaling by GPCR—PIK3CA—esophageal cancer	4.98e-06	2.66e-05	CbGpPWpGaD
Desipramine—CYP3A4—Metabolism—CYP1B1—esophageal cancer	4.96e-06	2.65e-05	CbGpPWpGaD
Desipramine—CHRM5—Signaling Pathways—MYC—esophageal cancer	4.94e-06	2.64e-05	CbGpPWpGaD
Desipramine—HTR2A—Signaling Pathways—ERBB2—esophageal cancer	4.94e-06	2.63e-05	CbGpPWpGaD
Desipramine—CHRM2—Signaling by GPCR—PIK3CA—esophageal cancer	4.94e-06	2.63e-05	CbGpPWpGaD
Desipramine—HRH1—Signaling Pathways—ERBB2—esophageal cancer	4.93e-06	2.63e-05	CbGpPWpGaD
Desipramine—CYP2B6—Metabolism—PTGS2—esophageal cancer	4.92e-06	2.63e-05	CbGpPWpGaD
Desipramine—CHRM1—Signaling Pathways—ERBB2—esophageal cancer	4.91e-06	2.62e-05	CbGpPWpGaD
Desipramine—CHRM3—Signaling Pathways—ERBB2—esophageal cancer	4.89e-06	2.61e-05	CbGpPWpGaD
Desipramine—HTR1A—Signaling Pathways—CDKN1A—esophageal cancer	4.88e-06	2.61e-05	CbGpPWpGaD
Desipramine—HTR2C—Signaling Pathways—CDKN1A—esophageal cancer	4.86e-06	2.59e-05	CbGpPWpGaD
Desipramine—ADRB1—Signaling Pathways—EP300—esophageal cancer	4.86e-06	2.59e-05	CbGpPWpGaD
Desipramine—CHRM2—Signaling Pathways—ERBB2—esophageal cancer	4.85e-06	2.59e-05	CbGpPWpGaD
Desipramine—CHRM5—Signaling Pathways—EGFR—esophageal cancer	4.83e-06	2.58e-05	CbGpPWpGaD
Desipramine—CYP2E1—Metabolism—PTGS2—esophageal cancer	4.82e-06	2.57e-05	CbGpPWpGaD
Desipramine—CHRM3—Metabolism—EP300—esophageal cancer	4.76e-06	2.54e-05	CbGpPWpGaD
Desipramine—ADRB2—Signaling Pathways—EP300—esophageal cancer	4.75e-06	2.54e-05	CbGpPWpGaD
Desipramine—CYP3A4—Metabolism—CYP19A1—esophageal cancer	4.67e-06	2.49e-05	CbGpPWpGaD
Desipramine—HTR1A—Signaling Pathways—EP300—esophageal cancer	4.65e-06	2.48e-05	CbGpPWpGaD
Desipramine—HTR2C—Signaling Pathways—EP300—esophageal cancer	4.62e-06	2.47e-05	CbGpPWpGaD
Desipramine—CYP2C19—Metabolism—CREBBP—esophageal cancer	4.54e-06	2.42e-05	CbGpPWpGaD
Desipramine—ABCB1—Metabolism—CREBBP—esophageal cancer	4.43e-06	2.37e-05	CbGpPWpGaD
Desipramine—DRD2—Signaling Pathways—CCND1—esophageal cancer	4.43e-06	2.37e-05	CbGpPWpGaD
Desipramine—CHRM4—Signaling Pathways—PIK3CA—esophageal cancer	4.38e-06	2.34e-05	CbGpPWpGaD
Desipramine—HTR2A—Signaling Pathways—CCND1—esophageal cancer	4.36e-06	2.33e-05	CbGpPWpGaD
Desipramine—HRH1—Signaling Pathways—CCND1—esophageal cancer	4.35e-06	2.32e-05	CbGpPWpGaD
Desipramine—CHRM1—Signaling Pathways—CCND1—esophageal cancer	4.34e-06	2.32e-05	CbGpPWpGaD
Desipramine—CHRM3—Signaling Pathways—CCND1—esophageal cancer	4.32e-06	2.31e-05	CbGpPWpGaD
Desipramine—DRD2—Signaling Pathways—CDKN1A—esophageal cancer	4.29e-06	2.29e-05	CbGpPWpGaD
Desipramine—CHRM2—Signaling Pathways—CCND1—esophageal cancer	4.28e-06	2.29e-05	CbGpPWpGaD
Desipramine—CYP3A4—Metabolism—HMOX1—esophageal cancer	4.26e-06	2.27e-05	CbGpPWpGaD
Desipramine—CHRM4—Signaling Pathways—TP53—esophageal cancer	4.24e-06	2.26e-05	CbGpPWpGaD
Desipramine—ADRB1—Signaling Pathways—MYC—esophageal cancer	4.23e-06	2.26e-05	CbGpPWpGaD
Desipramine—HTR2A—Signaling Pathways—CDKN1A—esophageal cancer	4.22e-06	2.25e-05	CbGpPWpGaD
Desipramine—HRH1—Signaling Pathways—CDKN1A—esophageal cancer	4.21e-06	2.25e-05	CbGpPWpGaD
Desipramine—CHRM1—Signaling Pathways—CDKN1A—esophageal cancer	4.2e-06	2.24e-05	CbGpPWpGaD
Desipramine—CHRM5—Signaling Pathways—PIK3CA—esophageal cancer	4.19e-06	2.24e-05	CbGpPWpGaD
Desipramine—CHRM3—Signaling Pathways—CDKN1A—esophageal cancer	4.18e-06	2.23e-05	CbGpPWpGaD
Desipramine—CYP2D6—Metabolism—CREBBP—esophageal cancer	4.18e-06	2.23e-05	CbGpPWpGaD
Desipramine—CHRM2—Signaling Pathways—CDKN1A—esophageal cancer	4.14e-06	2.21e-05	CbGpPWpGaD
Desipramine—ADRB2—Signaling Pathways—MYC—esophageal cancer	4.14e-06	2.21e-05	CbGpPWpGaD
Desipramine—ADRB1—Signaling Pathways—EGFR—esophageal cancer	4.14e-06	2.21e-05	CbGpPWpGaD
Desipramine—CYP2B6—Metabolism—EP300—esophageal cancer	4.09e-06	2.19e-05	CbGpPWpGaD
Desipramine—SLC22A2—Metabolism—PIK3CA—esophageal cancer	4.09e-06	2.18e-05	CbGpPWpGaD
Desipramine—CYP3A4—Metabolism—ABCB1—esophageal cancer	4.09e-06	2.18e-05	CbGpPWpGaD
Desipramine—DRD2—Signaling Pathways—EP300—esophageal cancer	4.08e-06	2.18e-05	CbGpPWpGaD
Desipramine—CYP2C19—Metabolism—NOS3—esophageal cancer	4.07e-06	2.17e-05	CbGpPWpGaD
Desipramine—CHRM5—Signaling Pathways—TP53—esophageal cancer	4.06e-06	2.17e-05	CbGpPWpGaD
Desipramine—ADRB2—Signaling Pathways—EGFR—esophageal cancer	4.05e-06	2.16e-05	CbGpPWpGaD
Desipramine—HTR1A—Signaling Pathways—MYC—esophageal cancer	4.05e-06	2.16e-05	CbGpPWpGaD
Desipramine—HTR2C—Signaling Pathways—MYC—esophageal cancer	4.03e-06	2.15e-05	CbGpPWpGaD
Desipramine—HTR2A—Signaling Pathways—EP300—esophageal cancer	4.01e-06	2.14e-05	CbGpPWpGaD
Desipramine—CYP2E1—Metabolism—EP300—esophageal cancer	4.01e-06	2.14e-05	CbGpPWpGaD
Desipramine—HRH1—Signaling Pathways—EP300—esophageal cancer	4.01e-06	2.14e-05	CbGpPWpGaD
Desipramine—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—esophageal cancer	4e-06	2.14e-05	CbGpPWpGaD
Desipramine—CHRM1—Signaling Pathways—EP300—esophageal cancer	3.99e-06	2.13e-05	CbGpPWpGaD
Desipramine—CHRM3—Signaling Pathways—EP300—esophageal cancer	3.98e-06	2.12e-05	CbGpPWpGaD
Desipramine—ABCB1—Metabolism—NOS3—esophageal cancer	3.97e-06	2.12e-05	CbGpPWpGaD
Desipramine—HTR1A—Signaling Pathways—EGFR—esophageal cancer	3.96e-06	2.11e-05	CbGpPWpGaD
Desipramine—CHRM2—Signaling Pathways—EP300—esophageal cancer	3.94e-06	2.1e-05	CbGpPWpGaD
Desipramine—HTR2C—Signaling Pathways—EGFR—esophageal cancer	3.94e-06	2.1e-05	CbGpPWpGaD
Desipramine—SLC22A1—Metabolism—PIK3CA—esophageal cancer	3.81e-06	2.03e-05	CbGpPWpGaD
Desipramine—CYP2A6—Metabolism—PIK3CA—esophageal cancer	3.75e-06	2e-05	CbGpPWpGaD
Desipramine—CYP2D6—Metabolism—NOS3—esophageal cancer	3.74e-06	2e-05	CbGpPWpGaD
Desipramine—CYP2C19—Metabolism—PTGS2—esophageal cancer	3.72e-06	1.99e-05	CbGpPWpGaD
Desipramine—ABCB1—Metabolism—PTGS2—esophageal cancer	3.63e-06	1.94e-05	CbGpPWpGaD
Desipramine—ADRB1—Signaling Pathways—PIK3CA—esophageal cancer	3.59e-06	1.92e-05	CbGpPWpGaD
Desipramine—DRD2—Signaling Pathways—MYC—esophageal cancer	3.56e-06	1.9e-05	CbGpPWpGaD
Desipramine—CYP1A2—Metabolism—CREBBP—esophageal cancer	3.54e-06	1.89e-05	CbGpPWpGaD
Desipramine—CHRM3—Metabolism—PIK3CA—esophageal cancer	3.52e-06	1.88e-05	CbGpPWpGaD
Desipramine—ADRB2—Signaling Pathways—PIK3CA—esophageal cancer	3.52e-06	1.88e-05	CbGpPWpGaD
Desipramine—HTR2A—Signaling Pathways—MYC—esophageal cancer	3.5e-06	1.87e-05	CbGpPWpGaD
Desipramine—HRH1—Signaling Pathways—MYC—esophageal cancer	3.49e-06	1.86e-05	CbGpPWpGaD
Desipramine—CHRM1—Signaling Pathways—MYC—esophageal cancer	3.48e-06	1.86e-05	CbGpPWpGaD
Desipramine—DRD2—Signaling Pathways—EGFR—esophageal cancer	3.48e-06	1.86e-05	CbGpPWpGaD
Desipramine—ADRB1—Signaling Pathways—TP53—esophageal cancer	3.48e-06	1.86e-05	CbGpPWpGaD
Desipramine—CHRM3—Signaling Pathways—MYC—esophageal cancer	3.47e-06	1.85e-05	CbGpPWpGaD
Desipramine—HTR1A—Signaling Pathways—PIK3CA—esophageal cancer	3.44e-06	1.83e-05	CbGpPWpGaD
Desipramine—CHRM2—Signaling Pathways—MYC—esophageal cancer	3.43e-06	1.83e-05	CbGpPWpGaD
Desipramine—CYP2D6—Metabolism—PTGS2—esophageal cancer	3.42e-06	1.83e-05	CbGpPWpGaD
Desipramine—HTR2A—Signaling Pathways—EGFR—esophageal cancer	3.42e-06	1.83e-05	CbGpPWpGaD
Desipramine—HTR2C—Signaling Pathways—PIK3CA—esophageal cancer	3.42e-06	1.83e-05	CbGpPWpGaD
Desipramine—HRH1—Signaling Pathways—EGFR—esophageal cancer	3.41e-06	1.82e-05	CbGpPWpGaD
Desipramine—CHRM1—Signaling Pathways—EGFR—esophageal cancer	3.4e-06	1.82e-05	CbGpPWpGaD
Desipramine—ADRB2—Signaling Pathways—TP53—esophageal cancer	3.4e-06	1.82e-05	CbGpPWpGaD
Desipramine—CHRM3—Signaling Pathways—EGFR—esophageal cancer	3.39e-06	1.81e-05	CbGpPWpGaD
Desipramine—CHRM2—Signaling Pathways—EGFR—esophageal cancer	3.36e-06	1.79e-05	CbGpPWpGaD
Desipramine—HTR1A—Signaling Pathways—TP53—esophageal cancer	3.33e-06	1.77e-05	CbGpPWpGaD
Desipramine—HTR2C—Signaling Pathways—TP53—esophageal cancer	3.31e-06	1.77e-05	CbGpPWpGaD
Desipramine—CYP1A2—Metabolism—NOS3—esophageal cancer	3.17e-06	1.69e-05	CbGpPWpGaD
Desipramine—CYP2C19—Metabolism—EP300—esophageal cancer	3.09e-06	1.65e-05	CbGpPWpGaD
Desipramine—CYP2B6—Metabolism—PIK3CA—esophageal cancer	3.03e-06	1.62e-05	CbGpPWpGaD
Desipramine—ABCB1—Metabolism—EP300—esophageal cancer	3.02e-06	1.61e-05	CbGpPWpGaD
Desipramine—DRD2—Signaling Pathways—PIK3CA—esophageal cancer	3.02e-06	1.61e-05	CbGpPWpGaD
Desipramine—HTR2A—Signaling Pathways—PIK3CA—esophageal cancer	2.97e-06	1.58e-05	CbGpPWpGaD
Desipramine—CYP2E1—Metabolism—PIK3CA—esophageal cancer	2.97e-06	1.58e-05	CbGpPWpGaD
Desipramine—HRH1—Signaling Pathways—PIK3CA—esophageal cancer	2.96e-06	1.58e-05	CbGpPWpGaD
Desipramine—CHRM1—Signaling Pathways—PIK3CA—esophageal cancer	2.95e-06	1.58e-05	CbGpPWpGaD
Desipramine—CHRM3—Signaling Pathways—PIK3CA—esophageal cancer	2.94e-06	1.57e-05	CbGpPWpGaD
Desipramine—DRD2—Signaling Pathways—TP53—esophageal cancer	2.92e-06	1.56e-05	CbGpPWpGaD
Desipramine—CHRM2—Signaling Pathways—PIK3CA—esophageal cancer	2.92e-06	1.56e-05	CbGpPWpGaD
Desipramine—CYP1A2—Metabolism—PTGS2—esophageal cancer	2.9e-06	1.55e-05	CbGpPWpGaD
Desipramine—HTR2A—Signaling Pathways—TP53—esophageal cancer	2.87e-06	1.53e-05	CbGpPWpGaD
Desipramine—HRH1—Signaling Pathways—TP53—esophageal cancer	2.87e-06	1.53e-05	CbGpPWpGaD
Desipramine—CHRM1—Signaling Pathways—TP53—esophageal cancer	2.86e-06	1.53e-05	CbGpPWpGaD
Desipramine—CHRM3—Signaling Pathways—TP53—esophageal cancer	2.85e-06	1.52e-05	CbGpPWpGaD
Desipramine—CYP2D6—Metabolism—EP300—esophageal cancer	2.85e-06	1.52e-05	CbGpPWpGaD
Desipramine—CHRM2—Signaling Pathways—TP53—esophageal cancer	2.82e-06	1.51e-05	CbGpPWpGaD
Desipramine—CYP3A4—Metabolism—CREBBP—esophageal cancer	2.73e-06	1.46e-05	CbGpPWpGaD
Desipramine—CYP3A4—Metabolism—NOS3—esophageal cancer	2.45e-06	1.31e-05	CbGpPWpGaD
Desipramine—CYP1A2—Metabolism—EP300—esophageal cancer	2.41e-06	1.29e-05	CbGpPWpGaD
Desipramine—CYP2C19—Metabolism—PIK3CA—esophageal cancer	2.29e-06	1.22e-05	CbGpPWpGaD
Desipramine—CYP3A4—Metabolism—PTGS2—esophageal cancer	2.24e-06	1.19e-05	CbGpPWpGaD
Desipramine—ABCB1—Metabolism—PIK3CA—esophageal cancer	2.23e-06	1.19e-05	CbGpPWpGaD
Desipramine—CYP2D6—Metabolism—PIK3CA—esophageal cancer	2.11e-06	1.12e-05	CbGpPWpGaD
Desipramine—CYP3A4—Metabolism—EP300—esophageal cancer	1.86e-06	9.93e-06	CbGpPWpGaD
Desipramine—CYP1A2—Metabolism—PIK3CA—esophageal cancer	1.78e-06	9.52e-06	CbGpPWpGaD
Desipramine—CYP3A4—Metabolism—PIK3CA—esophageal cancer	1.38e-06	7.35e-06	CbGpPWpGaD
